Senology.org - Newsletter

International Senologic and Oncologic  Scientific Community (ISOSC) 

"Connecting specialists worldwide"

 Editor-in-Chief: Gian Paolo Andreoletti, MD

Subscribe       Unsubscribe       Contact       Back Issues     

 

Connecting Specialists Worldwide

SENOLOGY GROUP on LiINKEDIN now has more than 1000 MEMBERS! JOIN US!

Join us on  LinkedInResearchGateDoctorsbook, Twitter, Facebook, Google Groups, YouTube, SlideShare, Flickr, and share informations and opinions. Check out Senology.org Newspaper and follow our RSS feeds for real-time updates

Literature Selection

Discussion

  •   - "Breast cancer screening with mammography "  - Share your opinion on  LinkedIn®

Focus on - CLEOPATRA trial

Calendar of Events

Fragments of History

  • William S Halsted  (New York, 1852-1922),  "The results of radical operations  for the cure of carcinoma of the breast", Ann Surg. July 1907:46(1):1-19": The Operation -  (...) It must be our endeavor to trace more definitely the routes travelled in the metastases to bone, particularly to the humerus, for it is even possible in case of involvement of this bone that amputation of the shoulder joint plus a proper removal of the soft parts might eradicate the disease. So, too, it is conceivable that ultimately, when our knowledge of the lymphatics traversed in cases of femur involvement becomes sufficiently exact, amputation at the hip joint may seem indicated"

Literature Selection

Comment

  • "Metformin in the treatment of pancreatic cancer", Donghui Li,  Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
     
    "Patients with pancreatic cancer often have a high prevalence (80%) of concurrent diabetes or impaired glucose tolerance, which are characterized by peripheral insulin resistance.  Accumulating epidemiological and experimental evidence suggest metformin, the most commonly used antidiabetic drug, as an antitumor agent. In our retrospective study of 302 diabetic patients with pancreatic cancer, we observed that metformin users had 4 months longer overall survival time, 32% reduced risk of death, and about 2-fold higher 2-year survival rate than the nonmetformin group. These observations add supporting evidence for the antitumor activity of metformin. Findings from this retrospective investigation should prompt future research to test the hypothesis that metformin can be used as a supplemental therapy in the treatment of pancreatic cancer."
    (Comment on:  Sadeghi N et al.: "Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer", Clin Cancer Res. 2012 Mar 31. [Epub ahead of print])

Literature Selection

 

Senology.org collaborates with TalkAboutHealth.com - "Cancer questions, answers, and support". Follow the Expert Q&A Workshops and join the conversation.

TalkAboutHealth Q&A of the month 

"Ablation is a new procedure for the treatment of kidney cancer that has even fewer complications than laparoscopic or robotic surgery and also requires a much shorter recovery time. Until recently the only treatment option for kidney tumors was to surgically remove them, either by removing the entire kidney (radical nephrectomy) or by removing just the tumor and surrounding region of kidney (partial nephrectomy). More recently, new technologies allow tumors to be destroyed, rendering them essentially harmless, without them actually being removed. In one form of ablation, radiofrequency energy is used to heat up and destroy the tumor. In another, known as cryoablation, the tumors are frozen to very low temperatures (-40 degrees Celsius!) and thereby destroyed. It is not clear which patients are the best candidates for ablation. In general, it seems the best candidates are patients with tumors less than 4cm in size. Also, there is a small risk that the patient will require a second treatment, which must be considered as well. Finally, the data on long-term outcomes are still being collected, so patients who want the most “tried and true” methods might opt for a different procedure
(Answer by Jaime Landman, Department of Urology,University of California, Irvine , CA, USA)

 

Unsubscribe

     

www.senology.org